Lisocabtagene maraleucel for relapsed or refractory, aggressive B-cell non-Hodgkin Lymphoma – second line
Lisocabtagene maraleucel is in clinical development as a treatment for adult patients with aggressive B-cell non-Hodgkin lymphoma (NHL) who are relapsed or refractory to a single line of immunochemotherapy (and whom are ineligible for stem cell transplantation). In NHL, the affected lymphocytes start to multiply in an abnormal way and begin to collect in certain parts of the body such as the lymph nodes. Aggressive or high-grade lymphomas tend to grow very quickly. Relapsed means the lymphoma has responded to treatment but then returns, and refractory means the lymphoma has not responded to the initial treatment. Treatment options for relapsed/refractory aggressive B-cell lymphoma are limited.
Lisocabtagene maraleucel is an advanced immunotherapy administered intravenously that contains the patient’s own white blood cells (T-cells) that have been modified genetically in the laboratory so that they make a protein called chimeric antigen receptor (CAR). The CAR T-cells attach to a particular protein called CD19 on the surface of cancer cells resulting in the death of these cells. If licensed, will offer an additional treatment option for patients with relapsed/refractory, aggressive B-cell NHL who are not eligible for stem cell transplant.